Collectively, our data indicate that, in direct opposition to AD, carriers of APOE-ε4 have a decreased risk whereas carriers of APOE-ε2 have an increased risk to develop distinct chronic pain conditions. The gene discussed is APOE; the disease is Alzheimer disease.